{"id":942282,"date":"2026-03-05T11:57:06","date_gmt":"2026-03-05T16:57:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/"},"modified":"2026-03-05T11:57:06","modified_gmt":"2026-03-05T16:57:06","slug":"fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/","title":{"rendered":"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers"},"content":{"rendered":"
\n

HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1\/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs).<\/p>\n

The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics\u2019 investigational topically administered allogeneic fibroblast spheroid-based therapy, CYWC628, for the treatment of refractory DFUs. Participants will receive up to 12 weeks of treatment using either standard of care (SoC) plus a low or high dose of CYWC628, or SoC alone. FibroBiologics has completed site onboarding as outlined in the protocol for the clinical trial but will activate additional sites if needed to support recruitment objectives.<\/p>\n

\u201cThis clinical trial will assess wound healing outcomes, durability of response, and safety parameters through regular clinical observation, testing, and imaging evaluations. An interim analysis will be conducted after a predefined number of participants complete six weeks of treatment to assess primary safety and efficacy endpoints,\u201d said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.<\/p>\n

\u201cSuccessfully engaging all clinical trial sites is a critical step as we advance towards trial initiation to demonstrate the potential of fibroblast spheroid-based therapies as a major breakthrough in DFU treatment,\u201d said Pete O\u2019Heeron, Founder and Chief Executive Officer of FibroBiologics. \u201cWith site onboarding complete, our human trial partners are in place and we are now focused on disciplined execution. \u00a0We look forward to generating data that can clearly inform how this therapy fits into the future of chronic wound care.\u201d<\/p>\n

\n Southern Star Research<\/a>, a leading full-service Australian CRO with APAC coverage, is managing all aspects of the CYWC628 trial from start to finish. \u201cThe CYWC628 program is an excellent fit for Australia\u2019s ecosystem and Southern Star Research\u2019s expertise in complex early-phase trials. We look forward to generating high-quality data to support FibroBiologics\u2019 innovative fibroblast spheroid therapy for patients with refractory diabetic foot ulcers,\u201d said Lloyd Prescott, CEO of Southern Star Research.<\/p>\n

For more information, please visit FibroBiologics’\u00a0website<\/a>,\u00a0email FibroBiologics at\u00a0info@fibrobiologics.com<\/a> or follow FibroBiologics on LinkedIn<\/a>, YouTube<\/a>, Facebook<\/a> or X<\/a>.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements<\/strong>
\n
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics\u2019 clinical trials, and the potential clinical benefits of fibroblasts and fibroblast-derived materials, including being a major breakthrough in DFU treatment. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov<\/a>. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) the ability of FibroBiologics to successfully prosecute its patent applications, (d) FibroBiologics\u2019 ability to manufacture its product candidates; and (e) FibroBiologics\u2019 ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.<\/p>\n

\n About CYWC628<\/strong>
\n
CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy for wound healing. Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments.<\/p>\n

FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 weeks of treatment using either standard of care plus a low or high-dose of CYWC628, or standard of care only.<\/p>\n

\n About FibroBiologics<\/strong>\n <\/p>\n

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents\/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.\u00a0For more information, visit\u00a0www.FibroBiologics.com<\/a>.<\/p>\n

\n About Southern Star Research<\/strong>
\n
Southern Star Research is a full-service clinical research organization headquartered in Australia, guiding small and mid-sized biotech, pharmaceutical, and medical device companies to confidently navigate complex early-phase clinical development\u00a0globally. With a strong focus on quality, collaboration, and scientific excellence, Southern Star Research supports trials across a range of therapeutic areas and phases. For more information, email: media@southernstarresearch.com<\/a><\/p>\n

\n General Inquiries:<\/strong>
\n
\n info@fibrobiologics.com<\/a>\n <\/p>\n

\n Investor Relations:<\/strong>
\n
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1\/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs). The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics\u2019 investigational topically administered allogeneic fibroblast spheroid-based therapy, CYWC628, for the treatment of refractory DFUs. Participants will receive up to 12 weeks of treatment using either standard … <\/p>\n

Continue reading “FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942282","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1\/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs). The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics\u2019 investigational topically administered allogeneic fibroblast spheroid-based therapy, CYWC628, for the treatment of refractory DFUs. Participants will receive up to 12 weeks of treatment using either standard … Continue reading "FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-05T16:57:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FibroBiologics Completes Site Onboarding for Phase 1\\\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers\",\"datePublished\":\"2026-03-05T16:57:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/\"},\"wordCount\":965,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/\",\"name\":\"FibroBiologics Completes Site Onboarding for Phase 1\\\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=\",\"datePublished\":\"2026-03-05T16:57:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FibroBiologics Completes Site Onboarding for Phase 1\\\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/","og_locale":"en_US","og_type":"article","og_title":"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Market Newsdesk","og_description":"HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1\/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs). The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics\u2019 investigational topically administered allogeneic fibroblast spheroid-based therapy, CYWC628, for the treatment of refractory DFUs. Participants will receive up to 12 weeks of treatment using either standard … Continue reading \"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-05T16:57:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers","datePublished":"2026-03-05T16:57:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/"},"wordCount":965,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/","name":"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=","datePublished":"2026-03-05T16:57:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjIzNCM3NDY4NzY0IzIyNjM1MzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-completes-site-onboarding-for-phase-1-2-clinical-trial-for-cywc628-for-the-treatment-of-refractory-diabetic-foot-ulcers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FibroBiologics Completes Site Onboarding for Phase 1\/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942282"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942282\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}